Interview with Emily Cheah, General Manager, BRASS
Biomedical Research and Support Services Pte Ltd. is an NUS University spin-off that has been around for more than 14 years; last year the company name was changed to BRASS.…
Address: 33 Ubi Avenue 3,
#06-13/14 Vertex,
Singapore 408868.
33 Ubi Avenue 3, #06-13/14 Vertex, Singapore 408868.
33 Ubi Avenue 3, #06-13/14 Vertex, Singapore 408868.
33 Ubi Avenue 3, #06-13/14 Vertex,,Singapore
Tel: +65 6742 6007
Web: http://www.brass-asiapacific.com/c/
BRASS™ was conceived in the National University of Singapore (NUS) on May 1996 with the primary aim of supporting medical device development from concept into reality.
The brainchild of Assoc. Prof. Eugene Khor, BRASS™ is the answer to the biomedical industry’s need for vital infrastructure in support of the medical devices industry. BRASS™ was registered in December 1997 (hence “SINCE 1997”) and in April 1, 1999, the NUS incubation component of BRASS was granted permission to spin-off as a separate entity.
BRASS™ was awarded sole distributorship for the Charles River Endosafe brand of LAL Bacterial Endotoxin Test reagents in Singapore, Indonesia and Malaysia, an achievement that still remains to this day. With its growing success, BRASS™ was able to secure a partnership with the North American Science Associates, Inc. (NAMSA), the world leader in medical device safety evaluation, in July 2002. With this strategic alliance, BRASS™ is able to provide the full panel of GLP ISO 10993 biocompatibility testing, functional and performance studies, and material characterization to the medical device industry as well as gained the rights to distribute the full series of NAMSA Sterilization Assurance Products in several territories in the Asia Pacific region. In 2011, BRASS™ successfully attained representation for Charles River Biopharmaceutical Services in Singapore, Malaysia, Indonesia and Vietnam.
Thirteen years since its humble beginnings, BRASS™ has grown from strength to strength, and counts as its clients various multinational industry leaders, innovative start-ups and research institutes from the pharmaceutical and medical device industry in South East Asia.
Quality Product Provider: broad range of high quality and reliable media, packaging and sterilization assurance products.
Medical Device Expertise
Specialist in Microbiological Testing
Strategic and customized solutions for product development, regulatory compliance and quality assurance throughout the entire life-cycle of the medical device.
Biomedical Research and Support Services Pte Ltd. is an NUS University spin-off that has been around for more than 14 years; last year the company name was changed to BRASS.…
Changi Airport Group’s Ching Kiat LIM reflects on a challenging 2020 for the airline industry, Changi’s longstanding excellence in pharmaceutical distribution, and how COVID-19 has pushed a greater embrace of…
Andrew Frye of medtech giant Baxter outlines his management strategy for the diverse APAC region, how growth was achieved in 2020 despite the drop in non-essential hospital visits and treatments…
Singapore – despite its modest USD 1.22 billion domestic market – has long been one of Asia’s leading biopharmaceutical hubs and a magnet for top talent. Multitudes of biopharma and…
Singapore’s Institute of Mental Health offers a comprehensive range of psychiatric, rehabilitative, and psychotherapy services for the country’s population. CEO Associate Professor Daniel Fung discusses their work to transform mental…
Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers…
Medtech industry veteran Sanjay Prabhakaran outlines the footprint and strategy of women’s health specialist Hologic in the dynamic Asia-Pacific region, how it leveraged its molecular diagnostics expertise to pivot towards…
Novo Nordisk Singapore’s Praful Chakkarwar explains how he leverages his experience in a range of geographies in his current role, how COVID-19 has helped facilitate the affiliate’s digital transformation, the…
Nawal Roy of global digital health platform Holmusk which aims to establish data as a core utility to the treatment of behavioural health disorders explains the challenges of working in…
ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead…
As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other…
Dr Choong May Ling, Mimi, CEO of Singapore’s Health Sciences Authority (HSA), one of the leading regulatory bodies in the Asia-Pacific region, outlines the impact of Singapore’s status as a…
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems…
See our Cookie Privacy Policy Here
